Successful Treatment of Simultaneous Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: A Case Report

Overview

Journal Oncol Lett

Specialty Oncology

Date 2024 Mar 1

PMID 38426158

Authors

Yuki Amakusa

Tatsuro Suzuki

Yu Hikosaka

Masaya Takemura

Tetsuya Oguri

Affiliations

Soon will be listed here.

Abstract

The present report described the case of a 74-year-old male patient with asbestos exposure whose chest computed tomography revealed a right lower lobe nodule and right pleural effusion. Pleural biopsy led to the diagnosis of epithelial malignant pleural mesothelioma (cT2N0M0, stage IB). Combination therapy with cisplatin + pemetrexed led to the complete remission of malignant pleural mesothelioma; however, the right lower lobe nodule grew in size over time. The patient was subsequently diagnosed with lung adenocarcinoma (cT1aN0M0, stage IA1) by computed tomography-guided biopsy performed 18 months after chemotherapy initiation and achieved remission of lung adenocarcinoma with stereotactic radiotherapy. The patient was alive without recurrence at the 12-month follow-up. The present case illustrated that multiple active regimens are currently available for malignant pleural mesothelioma and lung cancer that can aid in the treatment of complex cases.

Citing Articles

Long-term survival with pemetrexed-based chemotherapy in a patient with metastatic lung adenocarcinoma of unclear primary origin harboring MTHFR C677T(T/T) mutation: a case report.

Yu Y, Li N, Wang J Front Oncol. 2025; 14:1435357.

PMID: 39906671 PMC: 11790433. DOI: 10.3389/fonc.2024.1435357.

References

Bianchi C, Bianchi T, Ramani L . Malignant mesothelioma of the pleura and other malignancies in the same patient. Tumori. 2007; 93(1):19-22. DOI: 10.1177/030089160709300104. View

Eba J, Nakamura K, Mizusawa J, Suzuki K, Nagata Y, Koike T . Stereotactic body radiotherapy versus lobectomy for operable clinical stage IA lung adenocarcinoma: comparison of survival outcomes in two clinical trials with propensity score analysis (JCOG1313-A). Jpn J Clin Oncol. 2016; 46(8):748-53. DOI: 10.1093/jjco/hyw058. View

Chang J, Senan S, Paul M, Mehran R, Louie A, Balter P . Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015; 16(6):630-7. PMC: 4489408. DOI: 10.1016/S1470-2045(15)70168-3. View

Imenpour H, Ivaldi G, Brianti A, Pastorino G, Biggi S, Auriati L . Synchronous occurrence of pulmonary adenocarcinoma and pleural diffuse malignant mesothelioma. Pathologica. 2014; 105(6):353-6. View

Fitzmaurice C, Akinyemiju T, Al Lami F, Alam T, Alizadeh-Navaei R, Allen C . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2018; 4(11):1553-1568. PMC: 6248091. DOI: 10.1001/jamaoncol.2018.2706. View

Bou-Samra P, Chang A, Azari F, Kennedy G, Segil A, Guo E . Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database. Cancer Med. 2023; 12(11):12208-12220. PMC: 10278474. DOI: 10.1002/cam4.5915. View

Ozbudak I, Ozbudak O, Arslan G, Erdogan A, Ozbilim G . Metachronous malignant mesothelioma and pulmonary adenocarcinoma. Turk Patoloji Derg. 2013; 29(1):83-6. DOI: 10.5146/tjpath.2013.01156. View

Niu X, Zhou C, Hu A, Su L, Lin D, Han H . Malignant mesothelioma without asbestos exposure diagnosed during EGFR-TKI treatment of lung adenocarcinoma: A case report. Cancer Treat Res Commun. 2021; 27:100345. DOI: 10.1016/j.ctarc.2021.100345. View

Henderson D, Rodelsperger K, Woitowitz H, Leigh J . After Helsinki: a multidisciplinary review of the relationship between asbestos exposure and lung cancer, with emphasis on studies published during 1997-2004. Pathology. 2005; 36(6):517-50. DOI: 10.1080/00313020400010955. View

10.

Butnor K, Brownlee N, Mahar A, Pavlisko E, Sporn T, Roggli V . Diffuse malignant mesothelioma and synchronous lung cancer: A clinicopathological study of 18 cases. Lung Cancer. 2016; 95:1-7. DOI: 10.1016/j.lungcan.2016.02.007. View

11.

Yates D, Corrin B, Stidolph P, Browne K . Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax. 1997; 52(6):507-12. PMC: 1758573. DOI: 10.1136/thx.52.6.507. View

12.

Flood T, Sekhon H, Seely J, Shamji F, Gomes M . Spontaneous pneumothorax and lung carcinoma: should one consider synchronous malignant pleural mesothelioma?. J Thorac Oncol. 2009; 4(6):770-2. DOI: 10.1097/JTO.0b013e3181a52c3f. View

13.

Okumura T, Okada M, Tsuji M, Inoue A, Ochiai Y . Mesothelioma with lung cancer complicating asbestosis. Acta Pathol Jpn. 1980; 30(4):579-90. DOI: 10.1111/j.1440-1827.1980.tb01353.x. View

14.

Tsuzuki T, Ninomiya H, Natori Y, Ishikawa Y . Coalescent pleural malignant mesothelioma and adenocarcinoma of the lung, involving only minor asbestos exposure. Pathol Int. 2008; 58(7):451-5. DOI: 10.1111/j.1440-1827.2008.02253.x. View

15.

Postmus P, Kerr K, Oudkerk M, Senan S, Waller D, Vansteenkiste J . Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv1-iv21. DOI: 10.1093/annonc/mdx222. View

16.

Hamaji M, Chen F, Matsuo Y, Kawaguchi A, Morita S, Ueki N . Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer. Ann Thorac Surg. 2015; 99(4):1122-9. DOI: 10.1016/j.athoracsur.2014.11.009. View

17.

Sauter J, Dacic S, Galateau-Salle F, Attanoos R, Butnor K, Churg A . The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. J Thorac Oncol. 2022; 17(5):608-622. DOI: 10.1016/j.jtho.2021.12.014. View

18.

Allen T, Moran C . Synchronous pulmonary carcinoma and pleural diffuse malignant mesothelioma. Arch Pathol Lab Med. 2006; 130(5):721-4. DOI: 10.5858/2006-130-721-SPCAPD. View

19.

Lee A, Soomro I . Collision tumour of the pleura composed of small cell carcinoma and malignant mesothelioma. Histopathology. 2004; 45(3):305-6. DOI: 10.1111/j.1365-2559.2004.01900.x. View

20.

Vogelzang N, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P . Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21(14):2636-44. DOI: 10.1200/JCO.2003.11.136. View